Publication | Closed Access

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

MedicinePhase IiiPathologyEnsure StudyCancer TreatmentCancer GeneticsOncologyRadiation OncologyLung CancerMolecular Oncology